Meet our People
PSI will be presenting / exhibiting at the following conferences:
December 6-9, 2008
April 28-30, 2009
May 29-June 2, 2009
June 21-25, 2009
September 20-24, 2009
 |
ASH Annual Meeting, San Francisco, CA |
|
Partnerships with CROs, Orlando, FL |
|
ASCO, Orlando, FL |
|
DIA, San Diego, CA |
|
ECCO 2009, Berlin |
Contact
PrintNews
November 2008
PSI Aces FDA Inspections
Over the past month, PSI-managed trial sites have successfully undergone two FDA inspections following completion of a pivotal phase III registration program in prostate cancer. No findings were made in either of the two inspections.
Overall, PSI-managed studies have been through twenty-four audits by the FDA. Download pdf
Clinical Trial News
November 2008: Week 45
PSI Aces FDA Inspections
Over the past month, PSI-managed trial sites have successfully undergone two FDA inspections following completion of a pivotal phase III registration program in prostate cancer. No findings were made in either of the two inspections.
Overall, PSI-managed studies have been through twenty-four audits by the FDA. Download pdf
Clinical Trial News
November 2008: Week 45
- PSI completed enrollment in a phase III study of a novel antiemetic for the prevention of chemotherapy-induced nausea and vomiting.
- PSI completed the active treatment period of a phase III study of a novel antiviral product in patients with oral herpes.
- PSI completed the active treatment period of a phase II study of a novel antipsychotic in patients with schizophrenia.
- PSI completed a phase III study of a novel hormonal agent in patients with hormone-sensitive prostate cancer.
- PSI completed a proof-of-principle study of a novel disease-modifying agent in patients with rheumatoid arthritis.
- PSI reached an interim objective of 150 randomized patients in a phase III study in metastatic NSCLC.
- PSI reached an interim enrollment objective of 200 randomized patients in a phase II study of a novel prostaglandin modulator in persistent asthma.
- PSI launched a phase III study of a novel anticancer agent in patients with metastatic breast cancer.
- PSI reached an interim enrollment objective of 150 randomized patients in a phase III study of a novel antibiotic in patients with community-acquired pneumonia.
- PSI initiated enrollment in a phase III study of a novel anti-inflammatory agent in patients with knee osteoarthritis.
- PSI completed an exploratory study of a novel cancer vaccine in patients with renal cell carcinoma.
- PSI completed a phase II study of a novel analgesic in patients with post-surgical pain.
- PSI completed a proof-of-concept study of a novel immunomodulator in patients with allergic rhinitis.
- PSI initiated enrollment in a phase III study of a novel biological agent in patients with severe hemophilia.
- PSI completed the active treatment period of a phase II study a novel antibiotic in patients with complicated skin and skin structure infections.
- PSI reached an interim enrollment target of 150 randomized patients in a phase II study of a novel prostaglandin modulator in persistent asthma.
- PSI reached an interim enrollment objective of 50 randomized pediatric patients in a phase II study of a novel antiemetic for the prevention of post-operative nausea and vomiting.
- PSI reached an interim enrollment objective of 350 randomized patients in a phase II/III study of a novel biological agent in patients with metastatic renal cancer.
June 2008: PSI GAINS A FIRM FOOTHOLD IN LATIN AMERICA Download pdf